share_log

Aditxt | 8-K: Current report

Aditxt | 8-K: Current report

Aditxt | 8-K:重大事件
美股SEC公告 ·  10/31 04:19

牛牛AI助理已提取核心訊息

On October 28, 2024, Aditxt, Inc., a Delaware-based biotech company, entered into a significant agreement with Evofem Biosciences, Inc., purchasing 2,280 shares of Evofem Series F-1 Convertible Preferred Stock for $2,280,000. This transaction was accompanied by a Registration Rights Agreement, ensuring Evofem would file a registration statement for the resale of common stock issuable upon conversion of the preferred stock. The event also featured a fireside chat with Aditxt's CEO, Amro Albanna, and Evofem's CEO, Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion highlighted Aditxt's commitment to women's health, showcasing products like Phexxi®, a hormone-free contraceptive, and SOLOSEC®, a treatment for bacterial vaginosis and trichomoniasis. The conversation also touched on the potential for early detection of conditions like endometriosis through Aditxt's subsidiary, Pearsanta. The acquisition of Evofem by Aditxt is still in progress, pending the satisfaction of closing conditions, including the resolution of a senior loan.
On October 28, 2024, Aditxt, Inc., a Delaware-based biotech company, entered into a significant agreement with Evofem Biosciences, Inc., purchasing 2,280 shares of Evofem Series F-1 Convertible Preferred Stock for $2,280,000. This transaction was accompanied by a Registration Rights Agreement, ensuring Evofem would file a registration statement for the resale of common stock issuable upon conversion of the preferred stock. The event also featured a fireside chat with Aditxt's CEO, Amro Albanna, and Evofem's CEO, Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion highlighted Aditxt's commitment to women's health, showcasing products like Phexxi®, a hormone-free contraceptive, and SOLOSEC®, a treatment for bacterial vaginosis and trichomoniasis. The conversation also touched on the potential for early detection of conditions like endometriosis through Aditxt's subsidiary, Pearsanta. The acquisition of Evofem by Aditxt is still in progress, pending the satisfaction of closing conditions, including the resolution of a senior loan.
2024年10月28日,總部位於特拉華州的生物技術公司aditxt與evofem biosciences公司達成重要協議,購買了2280股Evofem Series F-1可轉換優先股,金額爲228萬美元。此次交易附帶一項備案權協議,確保Evofem將爲普通股的轉股發行註冊聲明。現場還舉行了一場由Aditxt的首席執行官Amro Albanna和Evofem的首席執行官Saundra Pelletier參與的爐邊聊天,由Drew Pinsky博士主持。討論突出了Aditxt對婦女健康的承諾,展示了象Phexxi®這樣的無激素避孕產品,和SOLOSEC®,一種治療細菌性陰道病和滴蟲病的藥物。討論還涉及通過Aditxt的子公司Pearsanta對諸如子宮內膜異位症這類疾病的早期檢測潛力。Aditxt對Evofem的收購仍在進行中,等待關閉條件的滿足,包括高級貸款的解決。
2024年10月28日,總部位於特拉華州的生物技術公司aditxt與evofem biosciences公司達成重要協議,購買了2280股Evofem Series F-1可轉換優先股,金額爲228萬美元。此次交易附帶一項備案權協議,確保Evofem將爲普通股的轉股發行註冊聲明。現場還舉行了一場由Aditxt的首席執行官Amro Albanna和Evofem的首席執行官Saundra Pelletier參與的爐邊聊天,由Drew Pinsky博士主持。討論突出了Aditxt對婦女健康的承諾,展示了象Phexxi®這樣的無激素避孕產品,和SOLOSEC®,一種治療細菌性陰道病和滴蟲病的藥物。討論還涉及通過Aditxt的子公司Pearsanta對諸如子宮內膜異位症這類疾病的早期檢測潛力。Aditxt對Evofem的收購仍在進行中,等待關閉條件的滿足,包括高級貸款的解決。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。